The aging of the worldwide population and a focus on lifestyle treatments that revitalize youthfulness and stave off skin damage are the driving forces behind a healthy prescription dermatological drug market, which should see sales jump to $11.1 billion by 2010, according to
a new study from the market research firm Kalorama Information, a division of MarketResearch.com, the leading provider of industry-specific market research reports.
With 2005 sales reaching $8.4 billion, The Worldwide Market for Prescription Dermatological Drugs predicts that sales in the antiaging, photodamage, hair treatment, psoriasis, and skin cancer segments will grow further at a rate of 5.7% over the next four years as consumer demand for newer and better derma drugs continues to increase as the aging population struggles to deal with a myriad of skin disorders and diseases.
While sales of prescription acne, Rosacea, dermatitis, seborrhea, and hyperpigmentation/melasma products have continued to perform well-although with slower growth rates during the last five years as many of these drugs are older or have lost patent protection-the overall market has been bolstered by recent trends in cosmeceuticals, a favorite among aging Baby Boomers.
"The aging population is better educated and wants to see results-whether they have wrinkles, skin cancer, or psoriasis. Today's consumers are savvy to innovative dermatological treatments, derma drug delivery developments, and new prescription drug information which is widely available on the internet," notes Mary Anne Crandall, RN, the author of the final report. "This has changed the face of dermatology as cosmetic dermatology is now in vogue and manufacturers are racing to find new treatments to satiate public demand."
With 2005 sales reaching $8.4 billion, The Worldwide Market for Prescription Dermatological Drugs predicts that sales in the antiaging, photodamage, hair treatment, psoriasis, and skin cancer segments will grow further at a rate of 5.7% over the next four years as consumer demand for newer and better derma drugs continues to increase as the aging population struggles to deal with a myriad of skin disorders and diseases.
While sales of prescription acne, Rosacea, dermatitis, seborrhea, and hyperpigmentation/melasma products have continued to perform well-although with slower growth rates during the last five years as many of these drugs are older or have lost patent protection-the overall market has been bolstered by recent trends in cosmeceuticals, a favorite among aging Baby Boomers.
"The aging population is better educated and wants to see results-whether they have wrinkles, skin cancer, or psoriasis. Today's consumers are savvy to innovative dermatological treatments, derma drug delivery developments, and new prescription drug information which is widely available on the internet," notes Mary Anne Crandall, RN, the author of the final report. "This has changed the face of dermatology as cosmetic dermatology is now in vogue and manufacturers are racing to find new treatments to satiate public demand."
